ArticleThe Lancet. Rheumatology2020
Mavrilimumab for severe COVID-19.
Mohamad Amin Pourhoseingholi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it
ArticleThe Lancet. Rheumatology2020
Mohamad Amin Pourhoseingholi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.